Milrinone Powder

Milrinone API is produced through a combined process of targeted synthesis, recrystallization, and membrane separation refining, controlling organic impurities and metal residues from the source. Its main component content is stably ≥99.0%, and key indicators including related substances, residual solvents, bacterial endotoxins, and sterility meet injection-grade requirements. Milrinone Raw Material features uniform crystal form, no moisture absorption or caking, no degradation or discoloration during long-term storage, and is suitable for sterile preparations and high-end anti-tumor preparation production.

Milrinone Powder is a white to off-white crystalline powder with a particle size D90 ≤ 30 μm. With good flowability and stable solubility, it enables rapid preparation of injections or lyophilized powders, greatly improving preparation production efficiency and finished product qualification rate. The powder properties undergo strict quality control and meet the process requirements of injections, nano-preparations, targeted preparations, and other scenarios.

Milrinone API (CAS 78415-72-2) strongly inhibits PDE3, increases cAMP concentration in cardiomyocytes, enhances myocardial contractility, dilates arteries and veins, and reduces cardiac preload and afterload. Its positive inotropic effect is 10–30 times that of amrinone, with mild effects on heart rate and mean arterial pressure. Clinical data demosntrates that intravenous administration takes effect in 5–15 minutes, with a half-life of 2–3 hours; cardiac output and cardiac index increase by more than 30%, pulmonary capillary wedge pressure decreases by ≥25%, and the rescue success rate is significantly improved for refractory heart failure ineffective to digitalis and diuretics. Its functions also involves improving tumor tissue perfusion, reversing multidrug resistance, and increasing tumor inhibition rate by ≥40% when combined with chemotherapeutic drugs.

Milrinone API does not significantly increase myocardial oxygen consumption, and the incidence of adverse reactions such as thrombocytopenia is less than 1%. It is safe for elderly and critically ill patients. The maximum daily dose is 1.13 mg/kg, with a treatment course ≤ 2 weeks. It has excellent safety and tolerability for short-term use and is suitable for ICU, emergency departments, operating rooms, and oncology centers.

We have signed long-term supply agreements with top GMP partner factories to quickly respond to urgent and bulk orders. MOQ for R&D trials is 10 g, and industrial production supports Bulk Milrinone large-scale procurement without delaying R&D and production schedules; long-term agreement supply is supported.

Products come from GMP, FDA, and CEP certified partner factories with full-process strict quality inspection. Key indicators are superior to international pharmacopoeia standards, and Milrinone API purity is stably ≥99.0%, providing core guarantee for preparation safety and R&D success.

We have mature global export experience, complete customs declaration, inspection, logistics, and documentation systems, and can legally supply Milrinone API (CAS 78415-72-2) to Europe, America, Japan, South Korea, Southeast Asia, the Middle East, South America, and other regions. Multilingual business support, 7×12-hour fast after-sales service, and stable replenishment are also provided.

A 7×12-hour fast-response after-sales system is established to quickly handle order, logistics, quality, and technical issues, ensuring a worry-free experience from consultation, procurement, and receipt to use.